Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P15088 (mast cell)
 14,925 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Human connective tissue type mast cells (CTMC) are frequently located in close proximity to microvascular and neural basement membranes (BM). We have explored the interaction between human dermal connective tissue-type (chymase positive) mast cells and laminin, a component of BM. In this report, we document that normal CTMC express laminin receptors and are intimately associated with laminin of BM in vivo and pericellular laminin complexes in vitro. Upon degranulation in vitro, CTMC-laminin complexes dissociate and CTMC do not adhere to laminin substrates. In cutaneous mastocytosis/urticaria pigmentosa, CTMC do not express laminin receptors detectable by immunohistochemistry, and are frequently not in close association with laminin of vascular BM. These same features could be induced by degranulation of normal mast cells in organ culture. These findings indicate that CTMC-laminin interactions may be important determinants of mast cell localization in tissue compartments.
 ...
PMID:Role of laminin in localization of human dermal mast cells. 192 33

Three cases of splenic involvement in three different types of generalized mastocytosis (systemic mast cell disease) are reported. The macroscopic, histological and ultrastructural modifications of the spleen are described. Each case exhibited a different morphological pattern. Giemsa staining, fluorescence after acridine orange staining and naphthol ASD chloracetate esterase reaction are shown to be valuable for diagnosis. By comparison, immunohistochemistry seemed not to be very useful, because no specific antigens are expressed. These findings are compared to previously published cases. Their value for the diagnosis and the prognosis are discussed.
 ...
PMID:Different patterns of spleen involvement in systemic and malignant mastocytosis. A histological and immunohistochemical study of three cases. 194 10

Mastocytoses are diseases caused by proliferating mast cells infiltrating one or more organs. The spectrum of mastocytosis includes the cutaneous forms urticaria pigmentosa and solitary mastocytoma (about 90% of mastocytoses) and systemic forms affecting other organs. Infiltrates are most often found in the bone marrow, spleen, lymph nodes and liver, but any organ may be affected. Patients with systemic mastocytosis may or may not have urticaria pigmentosa. About 35% of patients without urticaria pigmentosa have an associated malignant haematological disease and a poor prognosis. Symptoms caused by mast cell mediator release are best treated with antihistamines, but several other drugs may be used if the response is unsatisfactory. Many antineoplastic drugs have been tried to combat aggressive mastocytoses and mast cell leukaemia, but the results have been disappointing.
 ...
PMID:[Mastocytosis]. 195 56

Atopic dermatitis (AD), a common, multifactorial, and extremely complex disorder, should be examined from various points of view, and it requires all the skill a physician can gather because it can be a challenge for pediatricians, dermatologists, and allergists. The role of dietary factors in AD has long been a subject of controversies, and several investigators have demonstrated the effectiveness of elimination diets in the management of AD. The treatment of choice for AD due to food sensitivity (FS) is the elimination of the offending food(s). This can be easily achieved when the child is allergic to foods that are not common items in the diet or when the offending food is not an important nutrient. Problems arise when the child is allergic to food(s) common in the diet and/or that have a high nutritional value, SCG, the salt of a bischromone carboxylic acid, has been shown to be of some efficacy in the prophylaxis of bronchial asthma, allergic rhinitis, and other disorders associated with mast cell degranulation, such as mastocytosis. We reviewed 12 papers on the use of SCG in the management of AD children, which included 281 children aged 0.5 to 15 years. Analysis of the studies shows that five were carried out in the open, one in the single-blind, six in the double-blind fashion. Four out of five open trials yielded positive results, that is, SCG was effective in the management of AD. The double-blind studies were positive in three cases and negative in three. The only trial with doubtful results was conducted in the open fashion.
 ...
PMID:Oral sodium cromoglycate in the management of atopic dermatitis in children. 195 71

Urticaria pigmentosa is the most common form of mastocytosis, a disease in which abnormal proliferations of mast cells occur in various organs of the body. Multiple stimuli, including many drugs commonly used in anesthetic practice, can provoke mast cell degranulation and result in intraoperative hemodynamic instability. An anesthetic plan minimizing histamine release and utilizing vecuronium as the muscle relaxant is discussed, and the literature pertaining to urticaria pigmentosa is reviewed.
 ...
PMID:Urticaria pigmentosa: an anesthetic challenge. 197 52

We present the case of an adult patient with urticaria pigmentosa. The sudden presence of severe symptomatology (symptoms to mast cell mediators release), made us think of evaluating extracutaneous affection. Our results are consistent with recent reports in the medical literature. We have confirmed an increase of conjugated histamine levels (methyl-histamine) during the attack and its return to normal values after the treatment. For these reasons we comment on the importance of histamine levels in diagnosis and treatment control. The gastrointestinal biopsy suggestive of mastocytosis; the severe clinical manifestations, and the histamine metabolite levels during the clinical course, led us to include this case in the group of "indolent SMCD" according to the TRAVIS classification.
 ...
PMID:Urticaria pigmentosa. Histaminuria and treatment. 197 86

Ten patients with systemic mastocytosis (SM) were evaluated for their metabolic bone disease (4 men and 6 women; mean +/- SD, 59 +/- 13 yr). All patients presented with generalized osteopenia and/or atraumatic vertebral compression fractures. Three patients had long-standing urticaria pigmentosa; in these, the diagnosis of cutaneous mastocytosis had been established by skin biopsy. One of the 3 and 2 of the other 7 individuals had symptoms suggestive of SM. Although six patients had previously undergone decalcified bone marrow trephine core biopsy (DBMB), findings were consistent with SM in only 2 of them. X-Ray survey revealed generalized osteopenia in all 10 patients and vertebral compression fractures in 9. No patient had sclerotic bone lesions. Histological findings of undecalcified transiliac crest biopsy (UTBB) specimens from 9 patients (5 patients underwent both DBMB and UTBB, 4 underwent only UTBB, and 1 had only DBMB) disclosed bone marrow that contained nodules characteristic of mast cell granulomas and numerous scattered oval- and spindle-shaped mast cells. The trabecular bone contained abundant newly synthesized bone matrix and a significant increase in osteoblastic, osteoclastic, and resorptive surfaces. Dynamic histomorphometric parameters revealed a significantly increased mineral apposition rate. Our study suggests that SM may be a more frequent cause of osteoporosis than previously recognized. Generalized osteopenia with compression fractures may be the only presentation of SM. Undecalcified bone biopsy is useful in the diagnosis of SM. Accelerated bone remodeling is a characteristic histomorphometric feature of SM with diffuse osteopenia.
 ...
PMID:Systemic mastocytosis presenting as osteoporosis: a clinical and histomorphometric study. 198 13

Systemic mastocytosis is characterized by an abnormal proliferation of tissue mast cells. Symptoms of mastocytosis are primarily attributed to the release of mast cell mediators during episodes of systemic activation of the excessive numbers of mast cells. Thus, biochemical evidence for the release of increased quantities of mast cell secretory products can suggest or confirm, depending on the clinical situation, a diagnosis of systemic mastocytosis. A major advantage of the biochemical approach to the diagnosis of systemic mast cell disease is that it has allowed the recognition of a class of patients in whom episodes of systemic mastocytes activation can be unequivocally documented biochemically but in whom clear-cut evidence of abnormal mast cell proliferation is lacking by current histologic criteria. Although the release of increased quantities of mast cell mediators can be demonstrated during episodes of mast cell activation in such patients, mediator levels are usually normal at quiescent times. By contrast, patients with proliferative mast cell disease (mastocytosis) usually exhibit chronic overproduction of mast cell mediators. Mast cell secretory products that can be measured in an attempt to obtain biochemical evidence of systemic mast cell activation include histamine, prostaglandin D2, tryptase, and heparin. The analytical approaches to assessing release of those individual mast cell products are evaluated. In general, the diagnosis and investigation of patients with systemic mast cell activation can best be accomplished by concerted use of histologic examination of key tissues together with analysis of chemical markers of the mast cell.
 ...
PMID:Biochemical diagnosis of systemic mast cell disorders. 200 47

Mastocytosis is a disease characterized by an abnormal increase in mast cells. Manifestations of the disease are provoked in large part by the resultant increase in mast cell-derived mediators, which have a variety of local and systemic effects. Mastocytosis is variable in respect to the organ systems involved, clinical manifestations, and association with hematologic diseases. This has suggested the need for an improved classification scheme to allow assessment of prognosis and therapy. The heterogeneity of the disease patterns in mastocytosis strongly suggests that more than one biologic lesion may occur in the developmental sequence that leads to placement of mature mast cells in tissues.
 ...
PMID:Classification and diagnosis of mastocytosis: current status. 200 48

In systemic mastocytosis the liver, spleen, and lymph nodes may be infiltrated by mast cells, with patterns of infiltration specific for each tissue. This may result in hepatosplenomegaly and enlarged lymph nodes. Extensive involvement with mast cells may also be associated with organ dysfunction. Specifically, in the case of liver, mast cell infiltration may result in fibrosis, portal hypertension, and abdominal ascites. Clinically significant involvement of the liver, spleen, and lymph nodes appears to be more common in patients with aggressive forms of mastocytosis, including those with a hematologic disorder.
 ...
PMID:The liver, spleen, and lymph nodes in mastocytosis. 200 62


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>